FDA Approves Tirzepatide for Obstructive Sleep Apnea

What the FDA changed

Tirzepatide (Zepbound) is the first medication the FDA has approved specifically for moderate-to-severe obstructive sleep apnea in adults with obesity. The indication says it should be used with a reduced-calorie diet and increased physical activity.

That is a meaningful change. Obesity can contribute to upper-airway obstruction, but until this approval, no obesity medication carried a US indication for obstructive sleep apnea. Tirzepatide activates glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, which reduces appetite and food intake. The FDA said the improvement in sleep apnea severity was probably tied to weight reduction.

The population covered by the indication is narrow enough to matter. It includes adults with obesity and moderate-to-severe obstructive sleep apnea. For the pivotal trials, participants needed a body mass index of at least 30 and an apnea-hypopnea index, or AHI, of at least 15 events per hour.

There is no requirement in the label that a patient first fail PAP or prove that the device cannot be tolerated. I underlined that line in the notebook. The trial numbers take up more space, but this may be the detail people miss.

The size of the treatment effect

The approval came from SURMOUNT-OSA, a program consisting of two randomized, double-blind, placebo-controlled phase 3 trials. Together, they included 469 adults who were followed for 52 weeks. Every participant had obesity and moderate-to-severe obstructive sleep apnea, and none had diabetes.

The two trials reflected different experiences with PAP. One included 234 adults who were unable or unwilling to use it. The other included 235 adults who already used PAP and planned to continue. Participants received once-weekly tirzepatide at the maximum dose they could tolerate or placebo.

Researchers primarily wanted to know how much AHI changed after 52 weeks. AHI measures the average number of apnea and hypopnea episodes per hour of sleep. A lower number generally indicates less severe sleep-disordered breathing.

Among participants who were not using PAP, mean AHI dropped by 25.3 events per hour with tirzepatide and by 5.3 with placebo. The estimated difference between treatments was minus 20.0 events per hour, with a 95% confidence interval from minus 25.8 to minus 14.2.

The results were similar in the PAP trial. Mean AHI declined by 29.3 events per hour with tirzepatide, compared with 5.5 for placebo. The estimated treatment difference was minus 23.8 events per hour, with a 95% confidence interval from minus 29.6 to minus 17.9.

One part of the study design needs to stay attached to those figures. PAP was temporarily withdrawn before the sleep-study assessments, which allowed researchers to measure the apnea that remained underneath the device’s immediate mechanical effect.

Another result is more concrete. After 52 weeks, 42.2% of people receiving tirzepatide in the non-PAP trial had either an AHI below 5 or mild disease without excessive daytime sleepiness. That happened in 15.9% of the placebo group. In the PAP trial, the corresponding figures were 50.2% and 14.3%.

Weight fell sharply. Mean body weight declined by 17.7% with tirzepatide and 1.6% with placebo in the non-PAP trial. Among PAP users, the declines were 19.6% and 2.3%.

Tirzepatide also improved prespecified secondary measures, including hypoxic burden, systolic blood pressure and patient-reported sleep-related impairment. The trials were not built to determine whether treatment prevents cardiovascular events or helps people live longer. Most of my notebook page is AHI figures. Those unanswered outcomes sit in two lines below them.

How to interpret PAP alongside tirzepatide

The trials address two different clinical situations. For adults who cannot or will not use PAP, tirzepatide reduced apnea severity as measured in a sleep study. For people already using PAP, the second trial showed an additional benefit, which supports treating obesity while the device continues to control airway obstruction during sleep.

Neither study directly compared tirzepatide with therapeutic PAP. The evidence therefore cannot tell us that medication controls airway collapse, oxygen loss or symptoms as dependably as PAP while weight loss is still developing, a process that unfolded across the 52-week trials rather than overnight. PAP physically keeps the airway open during sleep and remains a central treatment when reliable nightly control is needed.

The PAP trial did not answer another common question: when can the device be reduced or stopped? Even after substantial weight loss, a person may still have clinically important apnea, particularly if the disease was severe at the start.

Coverage decisions may hinge on language that looks minor on the page. The sleep apnea indication requires obesity, rather than overweight plus another weight-related condition. It does not restrict treatment to patients who have failed PAP. Insurers and clinicians are likely to look for obesity and sleep-study-confirmed moderate-to-severe disease when deciding whether a patient matches the approved population.

I put a box around “obesity” in the notebook. It is part of the indication, not a loose piece of background.

Safety considerations before prescribing

The safety results from SURMOUNT-OSA generally matched what earlier tirzepatide studies had found. Gastrointestinal problems were the most common adverse events. Diarrhea, nausea, vomiting and constipation occurred more often with tirzepatide than with placebo. Most were described as mild to moderate.

Tirzepatide has a boxed warning based on thyroid C-cell tumors found in rats. It is not known whether the same risk occurs in humans. The medication is contraindicated for people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

The label also warns about pancreatitis, gallbladder disease, serious hypersensitivity reactions and acute kidney injury related to volume depletion. Hypoglycemia may occur if tirzepatide is taken with insulin or an insulin secretagogue. The FDA advises against using it with another product containing tirzepatide or with a GLP-1 receptor agonist.

Tirzepatide can cause fetal harm and should be discontinued once pregnancy is recognized. Its effect on gastric emptying may matter for people with severe gastrointestinal disease, patients taking oral medications, and those undergoing general anesthesia or deep sedation. That last concern can come up in sleep medicine, where some patients undergo sedated evaluations or airway procedures.

Important limits on the evidence

Both trials lasted 52 weeks. They excluded people with diabetes and were funded by the manufacturer. Random assignment strengthens the case that tirzepatide caused the measured differences, but there is less certainty about how the findings apply to people with diabetes, a BMI below 30, central sleep apnea, unstable heart or lung disease, or other conditions that were excluded or poorly represented.

AHI is a standard measure of sleep apnea severity, though it is still a surrogate rather than a cardiovascular or survival outcome. These trials do not establish that tirzepatide prevents heart attacks, strokes, arrhythmias, motor vehicle crashes or deaths in people with obstructive sleep apnea.

We also do not know enough about durability. Longer follow-up is needed to show what happens after tirzepatide is stopped and how often sustained weight loss changes a person’s PAP needs. I flipped back through the notebook to make sure. There is no number for either outcome.

Questions clinicians ask

Does the approval apply to adults who are overweight but not obese?

No. The obstructive sleep apnea indication applies to adults with obesity, and trial participants were required to have a BMI of at least 30. Tirzepatide has a separate indication for chronic weight management that covers some adults with overweight, but that does not broaden its sleep apnea indication.

Must a patient fail PAP before receiving tirzepatide?

No. The FDA indication does not include a PAP-failure requirement. One pivotal trial included adults who were unable or unwilling to use PAP, while the other studied adults who were already using the device and intended to continue.

Can PAP be stopped after weight loss or an improved AHI?

The trials did not test a plan for withdrawing PAP, and they did not identify a weight-loss threshold at which the device becomes unnecessary. Any decision about continued PAP would need to account for symptoms, clinical risk and a repeat objective assessment of sleep apnea rather than body weight alone.

What outcomes remain unproven?

During 52 weeks, tirzepatide improved AHI, hypoxic burden, body weight and several secondary measures. The studies did not establish reductions in cardiovascular events, accidents or deaths. They also did not show how long the apnea benefit lasts after treatment ends.

That final sentence trails off at the bottom of my notebook page.

Questions people ask

Who qualifies for tirzepatide for obstructive sleep apnea?

The FDA indication covers adults with obesity and moderate-to-severe obstructive sleep apnea. In the pivotal trials, participants had a BMI of at least 30 and an AHI of at least 15 events per hour.

Can tirzepatide replace PAP for sleep apnea?

The trials did not compare tirzepatide directly with therapeutic PAP or determine when PAP could be stopped. I read the evidence as support for treating obesity as part of sleep apnea care, not as proof that medication routinely replaces the device.

How much did tirzepatide improve sleep apnea in the trials?

After 52 weeks, participants receiving tirzepatide had much larger AHI reductions than those receiving placebo, both in the study of PAP users and in the study of people who did not use PAP. Tirzepatide also reduced weight and improved hypoxic burden and other measures. The trials did not show fewer cardiovascular events, accidents or deaths.

References

1. FDA Approves First Medication for Obstructive Sleep Apnea, U.S. Food and Drug Administration, 2024
2. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity, The New England Journal of Medicine, 2024
3. A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA), ClinicalTrials.gov, 2022
4. Sleep Apnea Treatment, National Heart, Lung, and Blood Institute, 2022